| Add to balance / Manage account | User: | Log out |
| Prospect News home > News index > List of issuers V > Headlines for ViRexx Medical Corp. > News item |
ViRexx says early results of phase 1 trial show Occlusin 50 Injection decreases liver cancer tumors
By E. Janene Geiss
Philadelphia, Nov. 16 - ViRexx Medical Corp. said interim research from its phase 1 clinical trial of the company's proprietary Occlusin 50 Injection embolotherapy shows it stabilizes liver cancer when used as part of a transcatheter arterial chemoembolization procedure.
Treatment and monitoring of five of a targeted 12 liver cancer patients has been completed, officials said in a company news release.
Interim results demonstrated stable disease for each of the five patients and no product-related severe adverse events, officials said.
Four of the five patients showed a decrease in tumor volume ranging from 8% to 27%, officials said.
"Our early expectations for the phase 1 trial have been confirmed by these positive interim results. Demonstrating not only safety but stable disease in this initial population is an important milestone for our Occlusin therapy platform," ViRexx chief executive officer Lorne Tyrrell said in the release.
"The development progress of the Occlusin 50 Injection further demonstrates our ability to advance a broad pipeline of therapies which also includes OvaRex MAb, our late-stage phase 3 product for the treatment of ovarian cancer," Tyrrell said.
The Occlusin 50 Injection targets malignant tumors, such as liver cancer. ViRexx also is developing a medical device for the treatment of benign tumors, such as uterine fibroids, as part of the Occlusin technology platform.
ViRexx is an Edmonton, Alta.-based biotechnology company focused on development of novel therapeutic products for the treatment of cancers and chronic viral infections.
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.